{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:36:05Z","timestamp":1778182565364,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Cu 47\/4-2 (CC), Cu 47\/6-1 (CC), Cu 47\/9-1 (CC)"],"award-info":[{"award-number":["Cu 47\/4-2 (CC), Cu 47\/6-1 (CC), Cu 47\/9-1 (CC)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fine needle diathermy (FND) is an effective method to destroy and regress pathologic corneal blood and lymphatic vessels. However, it is unknown whether FND itself causes a rebound corneal neovascularisation and whether that can be prevented by VEGF blockade. In female BALB\/c mice, the suture-induced inflammatory corneal neovascularisation model was used to induce hem- and lymphangiogenesis. Thereafter, prevascularized mice were divided into 2 groups: the combination therapy group received FND cauterization and subsequent VEGF TrapR<jats:sub>1<\/jats:sub>R<jats:sub>2<\/jats:sub> eye drops three times per day whereas the monotherapy group was treated only with FND. Three, 7 and 14 days after the treatment, corneas were collected and stained with FITC-conjugated CD31 and LYVE-1 followed by Cy3-conjugated secondary antibody to quantify corneal blood and lymphatic vessels. Relative mRNA expression of VEGF in the cornea was quantified by using qPCR. FND cauterization as monotherapy significantly obliterated (lymph)angiogenesis at early time points; however, this treatment led to secondary corneal hem- and lymphangiogenesis associated with significant upregulation of pro(lymph)angiogenic VEGF-A, VEGF-C, VEGF-D and infiltration of macrophages. Combining FND cauterization with VEGF TrapR<jats:sub>1<\/jats:sub>R<jats:sub>2<\/jats:sub> treatment prevented the undesired effect of the FND procedure alone and significantly better regressed corneal blood and lymphatic vessels at 1 week after the treatment compared to monotherapy and control group (p\u2009&lt;\u20090.01).<\/jats:p>","DOI":"10.1038\/s41598-020-60705-z","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T11:03:21Z","timestamp":1583233401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Supplemental Anti Vegf A-Therapy Prevents Rebound Neovascularisation After Fine Needle Diathermy Treatment to Regress Pathological Corneal (LYMPH)Angiogenesis"],"prefix":"10.1038","volume":"10","author":[{"given":"Viet Nhat Hung","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2248-8441","authenticated-orcid":false,"given":"Yanhong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Cursiefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"60705_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000099253","volume":"92","author":"C Cursiefen","year":"2007","unstructured":"Cursiefen, C. Immune privilege and angiogenic privilege of the cornea. Chem. Immunol. Allergy 92, 50\u201357 (2007).","journal-title":"Chem. Immunol. Allergy"},{"key":"60705_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.preteyeres.2013.01.001","volume":"34","author":"F Bock","year":"2013","unstructured":"Bock, F. et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog. Retin. Eye Res. 34, 89\u2013124 (2013).","journal-title":"Prog. Retin. Eye Res."},{"key":"60705_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","volume":"43","author":"P Lee","year":"1998","unstructured":"Lee, P., Wang, C. C. & Adamis, A. P. Ocular neovascularization: An epidemiologic review. Surv. Ophthalmol. 43, 245\u2013269 (1998).","journal-title":"Surv. Ophthalmol."},{"key":"60705_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nri1224","volume":"3","author":"JW Streilein","year":"2003","unstructured":"Streilein, J. W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3, 879\u2013889 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"60705_CR5","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","volume":"117","author":"B Bachmann","year":"2010","unstructured":"Bachmann, B., Taylor, R. S. & Curisfen, C. Corneal Neovascularization as a Risk Factor for Graft Failure and Rejection after Keratoplasty. Ophthalmol. 117, 1300\u20135.e7 (2010).","journal-title":"Ophthalmol."},{"key":"60705_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4049\/jimmunol.0903180","volume":"184","author":"T Dietrich","year":"2010","unstructured":"Dietrich, T. et al. Cutting Edge: Lymphatic Vessels, Not Blood Vessels, Primarily Mediate Immune Rejections After Transplantation. J. Immunol. 184, 535\u2013539 (2010).","journal-title":"J. Immunol."},{"key":"60705_CR7","doi-asserted-by":"publisher","unstructured":"Hos, D., Schlereth, S. L., Bock, F., Heindl, L. M. & Cursiefen, C. Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: What can we learn from the eye? Seminars in Cell and Developmental Biology (2015). https:\/\/doi.org\/10.1016\/j.semcdb.2014.11.003","DOI":"10.1016\/j.semcdb.2014.11.003"},{"key":"60705_CR8","first-page":"2176","volume":"36","author":"Y Sano","year":"1995","unstructured":"Sano, Y., Ksander, B. R. & Streilein, W. Fate of Orthotopic Corneal Allografts in Eyes That Cannot Support Anterior Chamber-Associated Immune Deviation Induction. Investig. Ophthalmol. Vis. Sci. 36, 2176\u20132185 (1995).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"60705_CR9","first-page":"413","volume":"37","author":"JW Streilein","year":"1996","unstructured":"Streilein, J. W., Bradley, D., Sano, Y. & Sonoda, Y. Immunosuppressive Properties of Tissues Obtained From Eyes With Experimentally Manipulated Corneas. Investig. Ophthalmol. Vis. Sci. 37, 413\u2013424 (1996).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"60705_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1084\/jem.20092277","volume":"208","author":"C Cursiefen","year":"2011","unstructured":"Cursiefen, C. et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J. Exp. Med. 208, 1083\u201392 (2011).","journal-title":"J. Exp. Med."},{"key":"60705_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","volume":"121","author":"C Cursiefen","year":"2014","unstructured":"Cursiefen, C. et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study. Ophthalmol. 121, 1683\u20131692 (2014).","journal-title":"Ophthalmol."},{"key":"60705_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/bjo.60.6.464","volume":"60","author":"PMH Cherry","year":"1976","unstructured":"Cherry, P. M. H. & Garner, A. Corneal neovascularization treated with argon laser. Brit. J. Ophthal 60, 464\u2013473 (1976).","journal-title":"Brit. J. Ophthal"},{"key":"60705_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/bjo.66.2.127","volume":"66","author":"RJ Marsh","year":"1982","unstructured":"Marsh, R. J. & Marshall, J. Treatment of lipid keratopathy with the argon laser. Br. J. Ophthalmol. 66, 127\u2013135 (1982).","journal-title":"Br. J. Ophthalmol."},{"key":"60705_CR14","doi-asserted-by":"crossref","unstructured":"Hou, Y. et al. Photodynamic therapy leads to time-dependent regression of pathologic corneal (lymph) angiogenesis and promotes high-risk corneal allograft survival. Investig. Ophthalmol. Vis. Sci. 58, (2017).","DOI":"10.1167\/iovs.17-22904"},{"key":"60705_CR15","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1111\/ajt.14874","volume":"18","author":"Y Hou","year":"2018","unstructured":"Hou, Y. et al. UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival. Am. J. Transplant. 18, 2873\u20132884 (2018).","journal-title":"Am. J. Transplant."},{"key":"60705_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","volume":"57","author":"JH Chang","year":"2012","unstructured":"Chang, J. H. et al. Corneal Neovascularization: An Anti-VEGF Therapy Review. Surv. Ophthalmol. 57, 415\u2013429 (2012).","journal-title":"Surv. Ophthalmol."},{"key":"60705_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Y Koenig","year":"2009","unstructured":"Koenig, Y. et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin\u00ae) eye drops against corneal neovascularization. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 247, 1375\u20131382 (2009).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"60705_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bjo.87.1.101","volume":"87","author":"C Cursiefen","year":"2003","unstructured":"Cursiefen, C., Hofmann-Rummelt, C., K\u00fcchle, M. & Schl\u00f6tzer-Schrehardt, U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br. J. Ophthalmol. 87, 101\u2013106 (2003).","journal-title":"Br. J. Ophthalmol."},{"key":"60705_CR19","first-page":"2148","volume":"41","author":"CT Pillai","year":"2000","unstructured":"Pillai, C. T., Dua, H. S. & Hossain, P. Fine needle diathermy occlusion of corneal vessels. Investig. Ophthalmol. Vis. Sci. 41, 2148\u20132153 (2000).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"60705_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/ICO.0b013e31823f8f7a","volume":"31","author":"Y Koenig","year":"2012","unstructured":"Koenig, Y., Bock, F., Kruse, F. E., Stock, K. & Cursiefen, C. Angioregressive Pretreatment of Mature Corneal Blood Vessels Before Keratoplasty: Fine-Needle Vessel Coagulation Combined With Anti-VEGFs. Cornea 31, 887\u2013892 (2012).","journal-title":"Cornea"},{"key":"60705_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/bjophthalmol-2014-304891","volume":"98","author":"L Faraj","year":"2014","unstructured":"Faraj, L., Elalfy, M., Said, D. & Dua, H. S. Fine needle diathermy occlusion of corneal vessels. Br. J. Ophthalmol. 98, 1287\u20131290 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"60705_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/bjophthalmol-2013-303729","volume":"98","author":"S Trikha","year":"2014","unstructured":"Trikha, S., Parikh, S., Osmond, C., Anderson, D. F. & Hossain, P. N. Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation. Br. J. Ophthalmol. 98, 454\u2013458 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"60705_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/ICO.0000000000000419","volume":"34","author":"U Elbaz","year":"2015","unstructured":"Elbaz, U., Mireskandari, K., Shen, C. & Ali, A. Corneal Fine Needle Diathermy With Adjuvant Bevacizumab to Treat Corneal Neovascularization in Children. Cornea 34, 773\u2013777 (2015).","journal-title":"Cornea"},{"key":"60705_CR24","first-page":"1","volume":"18","author":"R Hussain","year":"2016","unstructured":"Hussain, R. & Savant, V. Fine-Needle Diathermy with Simultaneous Subconjunctival Bevacizumab. Semin. Ophthalmol. 18, 1\u20133 (2016).","journal-title":"Semin. Ophthalmol."},{"key":"60705_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24037-3","volume":"8","author":"VNH Le","year":"2018","unstructured":"Le, V. N. H., Schneider, A. C., Scholz, R., Bock, F. & Cursiefen, C. Fine Needle-Diathermy Regresses Pathological Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Transplant Survival. Sci. Rep. 8, 5707 (2018).","journal-title":"Sci. Rep."},{"key":"60705_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2015.02.012","volume":"122","author":"N Spiteri","year":"2015","unstructured":"Spiteri, N. et al. Corneal angiography for guiding and evaluating fine-needle diathermy treatment of corneal neovascularization. Ophthalmol. 122, 1079\u20131084 (2015).","journal-title":"Ophthalmol."},{"key":"60705_CR27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1097\/ICO.0000000000000609","volume":"34","author":"V Romano","year":"2015","unstructured":"Romano, V. et al. Angiographic and In Vivo Confocal Microscopic Characterization of Human Corneal Blood and Presumed Lymphatic Neovascularization: A Pilot Study. Cornea 34, 1459\u201365 (2015).","journal-title":"Cornea"},{"key":"60705_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/ICO.0000000000001444","volume":"37","author":"VNH Le","year":"2018","unstructured":"Le, V. N. H., Hou, Y., Horstmann, J., Bock, F. & Cursiefen, C. Novel Method to Detect Corneal Lymphatic Vessels In Vivo by Intrastromal Injection of Fluorescein. Cornea 37, 267\u2013271 (2018).","journal-title":"Cornea"},{"key":"60705_CR29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/01.LAB.0000075642.11787.83","volume":"83","author":"S Yoshida","year":"2003","unstructured":"Yoshida, S., Yoshida, A., Matsui, H., Takada, Y. & Ishibashi, T. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab. Invest. 83, 927\u201338 (2003).","journal-title":"Lab. Invest."},{"key":"60705_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1172\/JCI20465","volume":"113","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen, C. et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113, 1040\u20131050 (2004).","journal-title":"J. Clin. Invest."},{"key":"60705_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-36526-6","volume":"9","author":"A Kiesewetter","year":"2019","unstructured":"Kiesewetter, A., Cursiefen, C., Eming, S. A. & Hos, D. Phase-specific functions of macrophages determine injury-mediated corneal hem- and lymphangiogenesis. Sci. Rep. 9, 1\u201316 (2019).","journal-title":"Sci. Rep."},{"key":"60705_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/bjo.2005.077875","volume":"90","author":"T Oshima","year":"2006","unstructured":"Oshima, T. et al. Analysis of corneal inflammation induced by cauterisation in CCR2 and MCP-1 knockout mice. Br. J. Ophthalmol. 90, 218\u2013222 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"60705_CR33","doi-asserted-by":"publisher","first-page":"11405","DOI":"10.1073\/pnas.0506112103","volume":"103","author":"C Cursiefen","year":"2006","unstructured":"Cursiefen, C. et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc. Natl. Acad. Sci. USA 103, 11405\u201311410 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60705_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1089\/jop.1999.15.413","volume":"15","author":"LG McNatt","year":"2009","unstructured":"McNatt, L. G., Weimer, L., Yanni, J. & Clark, A. F. Angiostatic Activity of Steroids in the Chick Embryo CAM and Rabbit Cornea Models of Neovascularization. J. Ocul. Pharmacol. Ther. 15, 413\u2013423 (2009).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"60705_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archophthalmol.2011.42","volume":"129","author":"D Hos","year":"2011","unstructured":"Hos, D. et al. Suppression of Inflammatory Corneal Lymphangiogenesis by Application of Topical Corticosteroids. Arch. Ophthalmol. 129, 445\u2013452 (2011).","journal-title":"Arch. Ophthalmol."},{"key":"60705_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.exer.2014.06.006","volume":"125","author":"P Mirabelli","year":"2014","unstructured":"Mirabelli, P., Peebo, B. B., Xeroudaki, M., Koulikovska, M. & Lagali, N. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Exp. Eye Res. 125, 118\u2013127 (2014).","journal-title":"Exp. Eye Res."},{"key":"60705_CR37","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1097\/ICO.0b013e318213f39f","volume":"30","author":"MM Steele","year":"2011","unstructured":"Steele, M. M., Kelley, P. M., Schieler, A. M. & Tempero, R. M. Glucocorticoids Suppress Corneal Lymphangiogenesis. Cornea 30, 1442\u20131447 (2011).","journal-title":"Cornea"},{"key":"60705_CR38","doi-asserted-by":"publisher","unstructured":"Bucher, F. et al. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol. (2014). https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02525.x","DOI":"10.1111\/j.1755-3768.2012.02525.x"},{"key":"60705_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00417-007-0683-5","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock, F. et al. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 246, 115\u2013119 (2008).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"60705_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","volume":"10","author":"W Stevenson","year":"2012","unstructured":"Stevenson, W., Cheng, S. F., Dastjerdi, M. H., Ferrari, G. & Dana, R. Corneal neovascularization and the utility of topical VEGF inhibition: Ranibizumab (Lucentis) Vs bevacizumab (Avastin). Ocul. Surf. 10, 67\u201383 (2012).","journal-title":"Ocul. Surf."},{"key":"60705_CR41","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/ICO.0000000000000507","volume":"34","author":"Y-R Park","year":"2015","unstructured":"Park, Y.-R. & Chung, S. K. Inhibitory Effect of Topical Aflibercept on Corneal Neovascularization in Rabbits. Cornea 34, 1303\u20137 (2015).","journal-title":"Cornea"},{"key":"60705_CR42","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1097\/TXD.0000000000000894","volume":"5","author":"D Hos","year":"2019","unstructured":"Hos, D. et al. Risk of Corneal Graft Rejection After High-Risk Keratoplasty Following Fine-Needle Vessel Coagulation of Corneal Neovascularization Combined With Bevacizumab: A Pilot Study. Transplant. Direct 5, e452 (2019).","journal-title":"Transplant. Direct"},{"key":"60705_CR43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.exer.2008.08.007","volume":"87","author":"F Bock","year":"2008","unstructured":"Bock, F. et al. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp. Eye Res. 87, 462\u2013470 (2008).","journal-title":"Exp. Eye Res."},{"key":"60705_CR44","first-page":"2127","volume":"43","author":"C Cursiefen","year":"2002","unstructured":"Cursiefen, C. et al. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Investig. Ophthalmol. Vis. Sci. 43, 2127\u20132135 (2002).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"60705_CR45","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock, F. et al. Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis. Investig. Ophthalmol. Vis. Sci. 48, 2545\u20132552 (2007).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"60705_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ajpath.2015.09.012","volume":"186","author":"D Hos","year":"2016","unstructured":"Hos, D. et al. IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages. Am. J. Pathol. 186, 159\u2013171 (2016).","journal-title":"Am. J. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60705-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:43:00Z","timestamp":1670312580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60705-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60705"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60705-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"19 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3908"}}